Study guide

9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

Key Takeaways Explain This Topic AI

Terms that constitute a diagnosis: apparent(ly), appears, comparable with, compatible with, consistent with, favor(s), malignant appearing, most likely, presumed, probable, suspect(ed), suspicious (for) and typical of.

Terms that do not constitute a diagnosis without more information: cannot be ruled out, equivocal, possible, potentially malignant, questionable, rule out, suggests and worrisome; synonyms such as "likely" do not count.

For intracranial and CNS sites only, "tumor" and "neoplasm" preceded by a reportable ambiguous term are reportable (2004+), but "mass" and "lesion" are not.

Cytology reported with an ambiguous term is not diagnostic by itself; the case is abstracted only when a positive biopsy or a physician's clinical impression of cancer supports it.

A later biopsy, resection or physician statement that disproves an ambiguous diagnosis means the case is not accessioned; the ambiguous-term lists are used only as "references of last resort."

Last updated: September 2026

The problem the lists solve

Clinicians hedge: "probable pancreatic carcinoma," "cannot rule out lymphoma." If each registrar interpreted these words differently, incidence counts would vary from registry to registry. STORE and the SEER Program Coding and Staging Manual therefore publish ambiguous terminology lists that give consistent answers for reportability. The same idea appears in the staging manuals, which have their own ambiguous-term rules for deciding whether a structure is involved.

The lists (STORE 2025)

  • Terms that constitute a diagnosis Terms that do not constitute a diagnosis without additional information
  • Apparent(ly) Cannot be ruled out
  • Appears Equivocal
  • Comparable with Possible
  • Compatible with Potentially malignant
  • Consistent with Questionable
  • Favors Rule out
  • Malignant appearing Suggests
  • Most likely Worrisome
  • Presumed
  • Probable
  • Suspect(ed)
  • Suspicious (for)
  • Typical of
  • Tumor and neoplasm : 2004+ diagnoses, only for C70.0–C72.9 and C75.1–C75.3

Rules for using the lists:

Words not on the list do not count. STORE says synonyms of these terms do not constitute a diagnosis ("likely" alone is not "most likely"). The SEER manual accepts a close grammatical form such as "favored" for "favors," but not true synonyms such as "supposed" for "presumed."

The term must modify a reportable diagnosis. "Consistent with carcinoma" is reportable. "Consistent with neoplasm" is not, except at intracranial and CNS sites, because "neoplasm" alone does not specify malignancy.

For CNS , "mass" and "lesion" are never reportable terms, even with a reportable ambiguous term in front of them.

The lists apply to any source document: pathology, imaging, operative and clinical reports. STORE's own example: a pathology report that says "suspicious for malignancy" is indicative of cancer.

"References of last resort"

STORE and the SEER manual state that the first resource for an unclear case is the physician who diagnosed or staged the tumor. Next come the full medical record and related reports. The ambiguous-terminology lists are used only when the situation remains unclear and cannot be discussed with the physician or pathologist. If the record contains a clear statement of malignancy, or a clear statement that there is none, do not use the lists.

Cytology: the key exception

Cytology described with an ambiguous term is not diagnostic by itself , even when the term (for example, "suspicious") is on the reportable list.

Abstract the case only when a positive biopsy or a physician's clinical impression of cancer supports the cytology.

Cytology that is positive for malignant cells is reportable.

Date of diagnosis: when a later definitive diagnosis confirms it, the date of the suspicious cytology or suspicious pathology becomes the date of diagnosis. STORE's example: cytology "suspicious" June 12, 2010, pathology positive July 2, 2010, so the date of diagnosis is June 12, 2010.

Resolving conflicting information

Situation Action

One report uses both a reportable and a non-reportable term (for example, "consistent with hepatocellular carcinoma" in the discussion and "possibly HCC" in the impression) Accession : accept the reportable term

The original source uses a non-reportable term ("possible melanoma"), and a later unrelated note lists "history of melanoma" with no treatment or other evidence Do not accession : give priority to the original source

Imaging is "suspicious for carcinoma," then biopsy or resection is negative Do not accession : the later tissue diagnosis disproves the ambiguous one

A physician documents a definitive clinical diagnosis of cancer and treats it, although the imaging report used a non-reportable term Accession : a physician's clinical diagnosis constitutes a diagnosis

"Malignant until proven otherwise," with no information to the contrary Accession (SEER), and update the case if later workup disproves it

"Highly suspicious for, but not diagnostic of, carcinoma" Do not accession (SEER treats this as equivalent to "not diagnostic")

A negative biopsy usually settles the question, but not always. If the managing physician still documents a clinical diagnosis of cancer and treats it despite a non-diagnostic biopsy, the physician's diagnosis governs. When in doubt, ask the physician.

Worked examples

CT impression: "3 cm right upper lobe mass, consistent with bronchogenic carcinoma." The patient declines biopsy and enters hospice. → Reportable ("consistent with"). Diagnostic Confirmation is 7 (radiography or imaging only), assuming the physician relies on the imaging.

CT impression: "Spiculated nodule; malignancy cannot be ruled out." No further workup. → Not reportable . Keep it in suspense if follow-up is expected.

Pleural fluid cytology: "Atypical cells suspicious for adenocarcinoma." No biopsy, and no physician statement of cancer. → Not reportable on cytology alone.

MRI brain: "Findings consistent with meningioma." → Reportable (a CNS tumor described with a reportable term). This is a non-malignant CNS case with Summary Stage 8.

MRI brain: "Enhancing lesion, probable glioma." → Reportable , because "probable" modifies a diagnosis (glioma), not the word "lesion."

Mammogram: "BI-RADS 5." → Not reportable for CoC on its own; it needs a biopsy or a physician's statement (STORE).

Loading diagram... Applying the ambiguous-term lists